Form 8-K - Current report:
SEC Accession No. 0001213900-21-045061
Filing Date
2021-08-26
Accepted
2021-08-26 16:39:33
Documents
13
Period of Report
2021-08-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea146488-8k_inmunebio.htm   iXBRL 8-K 26393
2 PRESS RELEASE DATED AUGUST 25, 2021 ea146488ex99-1_inmunebio.htm EX-99.1 13193
  Complete submission text file 0001213900-21-045061.txt   222763

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20210825.xsd EX-101.SCH 3027
4 XBRL LABEL FILE inmb-20210825_lab.xml EX-101.LAB 34915
5 XBRL PRESENTATION FILE inmb-20210825_pre.xml EX-101.PRE 22790
6 EXTRACTED XBRL INSTANCE DOCUMENT ea146488-8k_inmunebio_htm.xml XML 3877
Mailing Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037
Business Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 211212901
SIC: 2836 Biological Products, (No Diagnostic Substances)